Mithrl, which integrates its proprietary biomedical world model with the R&D systems of pharmaceutical companies, raised a $20M Series A led by Obvious Ventures (Natalie Breymeyer/Axios)
Mithrl says the new money will help push its biomedical AI infrastructure deeper into biopharma R&D.
The company raised a $20 million Series A led by Obvious Ventures, CEO Vivek Adarsh told Axios. Mithrl’s pitch is a proprietary biomedical world model connected directly to pharmaceutical companies’ research systems. The round is framed around expanding deployment of that infrastructure across biopharma. Techmeme's note
The company raised a $20 million Series A led by Obvious Ventures, CEO Vivek Adarsh told Axios. Mithrl’s pitch is a proprietary biomedical world model connected directly to pharmaceutical companies’ research systems. The round is framed around expanding deployment of that infrastructure across biopharma. Techmeme's note
score 6